Long-Term Outcome Following Radical Prostatectomy in Men With Clinical Stage T3 Prostate Cancer

Journal of Urology

Volumn 176, Issue 2, 2006, Pages 564-568

  Carver, Brett S ^a   Bianco Jr , Fernando J ^a   Scardino, Peter T ^a   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

prostate specific antigen; prostatectomy; prostatic neoplasms; recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; DATA ANALYSIS; DATA BASE; DEATH; EVALUATION; GLEASON SCORE; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; STATISTICAL MODEL;

FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745283388     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.03.093     Document Type: Article

References (20)

1. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing. 15-year outcome. BJU Int 95 (2005) 751
2. Zagars G.K., von Eschenbach A.C., and Ayala A.G. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 72 (1993) 1709
3. Hanks G.E., Krall J.M., Hanlon A.L., Asbell S.O., Pilepich M.V., and Owen J.B. Patterns of Care and RTOG studies in prostate cancer. long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys 28 (1994) 39
4. Zagars G.K., Johnson D.E., von Eschenbach A.C., and Hussey D.H. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate. long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 14 (1988) 1085
5. Granfors T., Modig H., Damber J.E., and Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement. a prospective randomized study. J Urol 159 (1998) 2030
6. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295
7. Crook J.M., Perry G.A., Robertson S., and Esche B.A. Routine prostate biopsies following radiotherapy for prostate cancer. results for 226 patients. Urology 45 (1995) 624
8. Zietman A.L., Westgeest J.C., and Shipley W.U. Radiation-based approaches to the management of T3 prostate cancer. Semin Urol Oncol 15 (1997) 230
9. Lerner S.E., Blute M.L., and Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer. outcome and contemporary morbidity. J Urol 154 (1995) 1447
10. Van den Ouden D., Hop W.C., and Schroder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160 (1998) 1392
11. Witjes W.P., Schulman C.C., Debruyne F.M., and The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-T3 N0 M0 prostatic carcinoma. Urology 49 (1997) 65
12. Amling C.L., Blute M.L., Bergstralh E.J., Slezak J.M., Martin S.K., and Zincke H. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol 15 (1997) 222
13. Soloway M.S., Sharifi R., Wajsman Z., McLeod D., Wood Jr. D.P., and Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 154 (1995) 424
14. Mordkin R.M., Hayes W.S., Kuettel M.R., and Lynch J.H. Management of locally advanced prostate cancer. Oncology 10 (1996) 1289
15. Pilepich M.V., Caplan R., Byhardt R.W., Lawton C.A., Gallagher M.J., Mesic J.B., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy. report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013
16. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EROTC study). a phase III randomised trial. Lancet 360 (2002) 103
17. Cadeddu J.A., Partin A.W., Epstein J.I., and Walsh P.C. Stage D1 (T1-3, N1-3, M0) prostate cancer. a case-controlled comparison of conservation treatment versus radical prostatectomy. Urology 50 (1997) 251
18. Coen J.J., Zietman A.L., Thakral H., and Shipley W.U. Radical radiation for localized prostate cancer. local persistence of disease results in a late wave of metastases. J Clin Oncol 20 (2002) 3199
19. Thompson I.M., Tangen C., Basler J., and Crawford E.D. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 168 (2002) 1008
20. Konety B.R., Eastham J.A., Reuter V.E., Scardino P.T., Donat S.M., Dalbagni G., et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer. results of a phase I/II study. J Urol 171 (2004) 709